SIRT1 and cancer: Although there are conflicting data about whether the SIRT1 agonist activity of RSV might alleviate glucose intolerance in humans, it is reasonable to suggest that the ability of RSV to mimic acarbose in enhancing anti-cancer T-cell immunity [101, 102] uncovers an immunologic dimension to the previously observed capacity of RSV to exert anti-diabetic effects via direct inhibition of GAA [51–54, 103–105].